Publicaciones de la Cátedra de Medicina Genómica

Publicaciones con filiación Universidad Continental de miembros de la Cátedra de Medicina Genómica

Jaramillo-Valverde L, Levano KS, Tarazona DD, Vasquez-Dominguez A, Toledo-Nauto A, Capristano S, Sanchez C, Tarazona-Santos E, Ugarte-Gil C, Guio H. GSTT1/GSTM1 Genotype and Anti-Tuberculosis Drug-Induced Hepatotoxicity in Peruvian Patients. Int J Mol Sci. 2022;23(19):11028. https://doi.org/10.3390/ijms231911028
Cacabelos R. Pharmacogenomics of Alzheimer’s and Parkinson’s diseases (2020). https://doi.org/10.1016/j.neulet.2018.09.018
Guerra, J., Cacabelos, R..Pharmacoepigenetics of Vertigo and Related Vestibular Syndromes (2019). Pharmacoepigenetics, pp. 755-779. https://doi.org/10.1016/B978-0-12-813939-4.00028-0
Cacabelos, R. Pathoepigenetics: The Role of Epigenetic Biomarkers in Disease Pathogenesis (2019). Pharmacoepigenetics, pp. 139-189 https://doi.org/10.1016/B978-0-12-813939-4.00005-X
Cacabelos, R. Preface: Pharmacoepigenetics: A Long Way Ahead (2019). https://doi.org/10.1016/B978-0-12-813939-4.10000-2
Cacabelos, R., Carril, J.C., Sanmartín, A., Cacabelos, P. Pharmacoepigenetic Processors: Epigenetic Drugs, Drug Resistance, Toxicoepigenetics, and Nutriepigenetics (2019). Pharmacoepigenetics, pp. 191-424 https://doi.org/10.1016/B978-0-12-813939-4.00006-1
Cacabelos, R., Cacabelos, P., Carril, J.C. Epigenetics and Pharmacoepigenetics of Age-Related Neurodegenerative Disorders (2019) Pharmacoepigenetics, pp. 903-950. https://doi.org/10.1016/B978-0-12-813939-4.00038-3
Cacabelos, R. Epigenetics and Pharmacoepigenetics of Neurodevelopmental and Neuropsychiatric Disorders (2019) Pharmacoepigenetics, pp. 609-709. https://doi.org/10.1016/B978-0-12-813939-4.00022-X
Cacabelos, R., Tellado, I., Cacabelos, P. The Epigenetic Machinery in the Life Cycle and Pharmacoepigenetics (2019) Pharmacoepigenetics, pp. 1-100. https://doi.org/10.1016/B978-0-12-813939-4.00001-2
Cacabelos, R. Pharmacoepigenetics (2019) Pharmacoepigenetics, pp. 1-967. https://doi.org/10.1016/B978-0-12-813939-4.09990-3
Teijido, O., Cacabelos, R. Pharmacoepigenomic interventions as novel potential treatments for Alzheimer’s and Parkinson’s diseases (2018). https://doi.org/10.3390/ijms19103199
Cacabelos, R. Have there been improvements in Alzheimer’s disease drug discovery over the past 5 years? (2018). https://doi.org/10.1080/17460441.2018.1457645
Cacabelos, R. Population-level pharmacogenomics for precision drug development in dementia (2018). https://doi.org/10.1080/23808993.2018.1468218
Cacabelos, R. Pleiotropy and promiscuity in pharmacogenomics for the treatment of Alzheimer’s disease and related risk factors (2018). https://doi.org/10.2217/fnl-2017-0038
Cacabelos, R., Meyyazhagan, A., Carril, J.C., Cacabelos, P., Teijido, Ó. Pharmacogenetics of vascular risk factors in Alzheimer’s disease (2018). https://doi.org/10.3390/jpm8010003
Cacabelos, R., Teijido, O. Epigenetics of brain aging (2018). https://doi.org/10.1016/B978-0-12-811353-0.00074-9
Cacabelos, R., Lombardi, V., Fernández-Novoa, L., Carrera, I., Cacabelos, P., Corzo, L., Carril, J.C., Teijido, O. Basic and Clinical Studies With Marine LipoFishins and Vegetal Favalins in Neurodegeneration and Age-Related Disorders (2018). https://doi.org/10.1016/B978-0-444-64179-3.00006-2
Jaramillo-Valverde L, Levano KS, Tarazona DD, Vasquez-Dominguez A, Toledo-Nauto A, Capristano S, Sanchez C, Tarazona-Santos E, Ugarte-Gil C, Guio H. GSTT1/GSTM1 Genotype and Anti-Tuberculosis Drug-Induced Hepatotoxicity in Peruvian Patients. Int J Mol Sci. 2022;23(19):11028. https://doi.org/10.3390/ijms231911028
Jaramillo-Valverde, L., Levano, K. S., Tarazona, D. D., Capristano, S., Zegarra-Chapoñan, R., Sanchez, C., Yufra-Picardo, V. M., Tarazona-Santos, E., Ugarte-Gil, C., & Guio, H. (2022). NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients. Molecular Genetics & Genomic Medicine, 10, e1987. https://doi.org/10.1002/mgg3.1987

Referencias Bibliográficas del Director de la Cátedra de Medicina Genómica

2023

Martínez-Iglesias O, Naidoo V, Carril JC, Seoane S, Cacabelos N, Cacabelos R. Gene Expression Profiling as a Novel Diagnostic Tool for Neurodegenerative Disorders. Int J Mol Sci. 2023 Mar 17;24(6):5746. doi: 10.3390/ijms24065746. PMID: 36982820; PMCID: PMC10057696.
Martínez-Iglesias O, Naidoo V, Corzo L, Pego R, Seoane S, Rodríguez S, Alcaraz M, Muñiz A, Cacabelos N, Cacabelos R. DNA Methylation as a Biomarker for Monitoring Disease Outcome in Patients with Hypovitaminosis and Neurological Disorders. Genes (Basel). 2023 Jan 30;14(2):365. doi: 10.3390/genes14020365. PMID: 36833292; PMCID: PMC9956161.
Carrera I, Corzo L, Naidoo V, Martínez-Iglesias O, Cacabelos R. Cardiovascular and lipid-lowering effects of a marine lipoprotein extract in a high-fat diet-induced obesity mouse model. Int J Med Sci. 2023 Jan 22;20(3):292-306. doi: 10.7150/ijms.80727. PMID: 36860672; PMCID: PMC9969509.
Cacabelos R, Carril JC, Corzo L, Pego R, Cacabelos N, Alcaraz M, Muñiz A, Martínez-Iglesias O, Naidoo V. Pharmacogenetics of anxiety and depression in Alzheimer’s disease. Pharmacogenomics. 2023 Jan 11. doi: 10.2217/pgs-2022-0137. Epub ahead of print. PMID: 36628952.

2022

Martínez-Iglesias O, Carrera I, Naidoo V, Cacabelos R. AntiGan: An Epinutraceutical Bioproduct with Antitumor Properties in Cultured Cell Lines. Life (Basel). 2022 Jan 10;12(1):97. doi: 10.3390/life12010097. PMID: 35054489; PMCID: PMC8780983.
Martínez-Iglesias O, Naidoo V, Carrera I, Cacabelos R. Epigenetic Studies in the Male APP/BIN1/COPS5 Triple-Transgenic Mouse Model of Alzheimer’s Disease. Int. J. Mol. Sci. 2022, 23, 2446. https://doi.org/10.3390/ijms23052446.
Cacabelos R. What have we learnt from past failures in Alzheimer’s disease drug discovery?, Expert Opinion on Drug Discovery, DOI:10.1080/17460441.2022.2033724 (2022).
Guerra J , Naidoo V, Cacabelos R. Neurogenic dysphagia: current pharmacogenomic perspectives. J Transl Genet Genom 2022;6:304-21
DOI: 10.20517/jtgg.2022.08.
Cacabelos R. Preface. Central Nervous System Agents in Medicinal Chemistry, 2022; 22:1.
Cacabelos R. Preface. Current Pharmacogenomics and Personalized Medicine, 2022; 19:1.
Cacabelos R. Pharmacogenetics for improving efficacy and safety in drug development and for reducing costs in Alzheimer’s disease. Current Pharmacogenomics and Personalized Medicine, 2022; 19:3-6.
Martínez-Iglesias O, Naidoo V, Carrera I, Corzo L, Cacabelos R. Nosustrophine: An epinutraceutical bioproduct with effects on DNA methylation, histone acetylation and sirtuin expression in Alzheimer’s disease. Pharmaceutics 2022, 14, 2447. https//doi.org/10.3390/pharmaceutics14112447.

2021

Cacabelos R, Carrera I, Martínez-Iglesias O, Cacabelos N, Naidoo V. What is the gold standard model for Alzheimer’s disease drug discovery and development? Expert Opin Drug Discov. 2021 Dec;16(12):1415-1440. doi: 10.1080/17460441.2021.1960502. Epub 2021 Aug 25. PMID: 34330186.
Cacabelos R, Carrera I, Martínez O, Naidoo V, Cacabelos N, Aliev G, Carril JC. Influence of dopamine, noradrenaline, and serotonin transporters on the pharmacogenetics of Atremorine in Parkinson’s disease. Drug Dev Res. 2021 Aug;82(5):695-706. doi: 10.1002/ddr.21784. Epub 2021 Jan 17. PMID: 33458869.
Cacabelos R, Carrera I, Martínez O, Alejo R, Fernández-Novoa L, Cacabelos P, Corzo L, Rodríguez S, Alcaraz M, Nebril L, Tellado I, Cacabelos N, Pego R, Naidoo V, Carril JC. Atremorine in Parkinson’s disease: From dopaminergic neuroprotection to pharmacogenomics. Med Res Rev. 2021 Sep;41(5):2841-2886. doi: 10.1002/med.21838. Epub 2021 Jun 9. PMID: 34106485.
Cacabelos R, Naidoo V, Corzo L, Cacabelos N, Carril JC. Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions. Int J Mol Sci. 2021 Dec 10;22(24):13302. doi: 10.3390/ijms222413302. PMID: 34948113; PMCID: PMC8704264.
Cacabelos R, Naidoo V, Martínez-Iglesias O, Corzo L, Cacabelos N, Pego R, Carril JC. Personalized Management and Treatment of Alzheimer’s disease. Life 2022; 12, 460. https://doi.org/10.3390/life120030460.
Martínez-Iglesias O, Naidoo V, Cacabelos N, Cacabelos R. Epigenetic Biomarkers as Diagnostic Tools for Neurodegenerative Disorders. Int J Mol Sci. 2021 Dec 21;23(1):13. doi: 10.3390/ijms23010013. PMID: 35008438; PMCID: PMC8745005.

2020

Corzo L, Fernández-Novoa L, Carrera I, Martínez O, Rodríguez S, Alejo R, Cacabelos R. Nutrition, Health, and Disease: Role of Selected Marine and Vegetal Nutraceuticals. Nutrients. 2020 Mar 11;12(3):747. doi: 10.3390/nu12030747.
Cacabelos R. Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia. Int J Mol Sci. 2020 Apr 26;21(9):E3059. doi: 10.3390/ijms21093059.
Cacabelos R. Pharmacogenomics of Alzheimer’s and Parkinson’s diseases. Neurosci Lett. 2020 May 1;726:133807. doi: 10.1016/j.neulet.2018.09.018. Epub 2018 Sep 17.
Martínez-Iglesias O, Carrera I, Carril JC, Fernández-Novoa L, Cacabelos N, Cacabelos R. DNA Methylation in Neurodegenerative and Cerebrovascular Disorders. Int J Mol Sci. 2020 Mar 23;21(6):2220. doi: 10.3390/ijms21062220.
Cacabelos R. Pharmacogenomic of drugs to treat brain disorders. Expert Review of Precision Medicine and Drug Development 2020; DOI: 10.1080/23808992.2020.1738217.
Cacabelos R. Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opinion on Drug Metabolism & Toxicology, DOI: 10.1080/17425255.2020.1779700.
Cacabelos R, Takeda M. Santiago Ramón y Cajal: A genius in structural Neuroscience and achievements in his age. Jinmeikai Journal of Psychiatry 2020; 18:116-122.
Takeda M, Cacabelos R. Procesos degenerativos traumáticos de la corteza cerebral de Santiago Ramón y Cajal. Jinmeikai Journal of Psychiatry 2020; 18:123-135.
Cacabelos R. Towards a mature discipline of pharmacogenomics: Epistemological reflections. Current Pharmacogenomics and Personalized Medicine 2020; 17(1):3-6.
Martínez-Iglesias O, Naidoo V, Carril JC, Carrera I, Corzo L, Rodriguez S, Alejo R, Cacabelos N, Cacabelos R. AtreMorine treatment regulates DNA methylation in neurodegenerative disorders: Epigenetic and Pharmacogenetic Studies. Current Pharmacogenomics and Personalized Medicine, 2020; 17:159-171.

2019

Cacabelos R, Cacabelos N, Carril JC. The role of pharmacogenomics in adverse drug reactions. Expert Rev Clin Pharmacol. 2019 May;12(5):407-442. doi: 10.1080/17512433.2019.1597706. Epub 2019 Apr 24.
Cacabelos R, Carril JC, Cacabelos N, Kazantsev AG, Vostrov AV, Corzo L, Cacabelos P, Goldgaber D. Sirtuins in Alzheimer’s Disease: SIRT2-Related GenoPhenotypes and Implications for PharmacoEpiGenetics. Int J Mol Sci. 2019 Mar 12;20(5). pii: E1249. doi: 10.3390/ijms20051249.
Carrera I, Cacabelos R. Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease. Curr Neuropharmacol. 2019;17(3):295-306. doi: 10.2174/1570159X17666181127125704.
Lombardi VRM, Carrera I, Corzo L, Cacabelos R. Role of bioactive lipofishins in prevention of inflammation and colon cancer. Semin Cancer Biol. 2019; 56:175-184. 2017 Nov 24. pii: S1044-579X(17)30255-9. doi: 10.1016/j.semcancer.2017.11.012;
Guerra J, Cacabelos R. Genomics of speech and language disorders. J Transl Genet Genom 2019; 3:9. DOI: 10.20517/jtgg.2018.03.
Cacabelos R, Carrera I, Alejo R, Fernández-Novoa L, Cacabelos P, Corzo L, Rodríguez S, Alcaraz M, Tellado I, Cacabelos N, Pego R, Carril JC. Pharmacogenetics of Atremorine-induced neuroprotection and dopamine response in Parkinson’s disease. Planta Medica 2019; DOI https:// doi.org/10-1055/a-1013-7686.
Cacabelos R. How plausible is an Alzheimer’s disease vaccine? Expert Opin Drug Discov. 2019 Sep 17:1-6. doi: 10.1080/17460441.2019.1667329.
Carrera I, Martínez O, Cacabelos R. Neuroprotection with Natural Antioxidants and Nutraceuticals in the Context of Brain Cell Degeneration: The Epigenetic Connection. Curr Top Med Chem. 2019;19(32):2999-3011. doi: 10.2174/1568026619666191202155738.

2018

Cacabelos R, Meyyazhagan A, Carril JC, Cacabelos R, Teijido O. Pharmacogenetics of vascular risk factors in Alzheimer’s Disease. J Pers Med 2018; 8(3). Doi:10.3390/jpm8010003.
Lombardi, V.R., Carrera, I., Cacabelos, R. In vitro and in vivo cytotoxic effect of AntiGan against tumor cells. Experimental and Therapeutic Medicine, 2018; 15: 2547-2556.
Carrera I, Vigo C, Cacabelos R. A vaccine kit for prevention and therapy of Alzheimer’s disease in a transgenic mouse model. J Expl Res Pharmacol 2018; 3:12-18.
Cacabelos R. Pleiotropy and promiscuity in pharmacogenomics for the treatment of Alzheimer’s disease and related risk factors. Future Neurol 2018; 10.2217/fnl-2017.
Cacabelos R. Have there been improvement in Alzheimer’s disease drug discovery over the past 5 years? Expert Opin Drug Discov 2018; doi.org/10.1080/17460441.2018.1457645.
Cacabelos R. Pharmacogenomics of Alzheimer’s and Parkinson’s diseases. Neurosci Lett. 2018 Sep 17. pii: S0304-3940(18)30624-4. doi: 10.1016/j.neulet.2018.09.018.
Carrera I, Fernandez-Novoa L, Sampedro C, Tarasov VV, Aliev G, Cacabelos R. Dopaminergic neuroprotection with Atremorine in Parkinson’s disease. Current Medicinal Chemistry 2018; 25:5372-5388.
Lombardi VRM, Corzo L, Carrera I, Cacabelos R. The search for biomarine-derived compounds with immunomodulatory activity. J Explor Res Pharmacol 2018; 3:30-41.
Teijido O, Cacabelos R. Pharmacoepigenomic interventions as novel potential treatments for Alzheimer’s and Parkinson’s diseases. Int J Mol Sci 2018; 19, 3199; doi:10.3390/ijms19103199.
Olivier IS, Cacabelos R, Naidoo V. Risk factors and pathogenesis of HIV-associated neurocognitive disorder: The role of host genetics. Int J Mol Sci 2018; 19, 3594; doi:10.3390/ijms19113594.
Cacabelos R. Population-level pharmacogenomics for precision drug development in dementia, Expert Review of Precision Medicine and Drug Development, 2018; 3:3, 163-188, DOI: 10.1080/23808993.2018.1468218.
Carrera I, Fernandez-Novoa L, Sampedro C, Tarasov VV, Aliev G, Cacabelos R. Dopaminergic Neuroprotection with Atremorine in Parkinson´s Disease. Curr Med Chem. 2018;25(39):5372-5388. doi: 10.2174/0929867325666180410100559.

2017

Aliev G1, Barreto GE1, Cacabelos R1. Editorial: Genomics and Epigenomics of Tumor and Aging Cells. Curr Genomics. 2017 Oct;18(5):375-377. doi: 10.2174/138920291805170817124855.
Arun M, Meenakshi RN, Kumar AK, Kumar RKM, Haripriya KB, Balamuralikrishnan B, Kumar AA, Muguresh E, Shanmughavel P, Sasikala K, Cacabelos R. Cytogenetic screening and promotor CpG-island methylation of brain-derived neurotrophic factor (BDNF) gene in schizophrenia and Parkinson’s disease patients from India. J Genomic Med Pharmacogenomics 2017; 1(2): 242-257.
Balamuralikrishnan B, Haripriya KB, Meenakshi RN, Arun M, Kumar AK, Sureshkumar S, Murugesh E, Christy IK, Kumar RKM, Kumar KP, Shanmughavel S, Vijay A, Younis M, Teijido O, Carril JC, Cacabelos P, Sasikala K, Cacabelos R. Cytogenetic and molecular study of children with Down’s syndrome in India: Influence of maternal hypothyroidism. J Genomic Med Pharmacogenomics 2017; 2(1): 258-266.
Cacabelos R, Carrera I, Fernández-Novoa L, Alejo R, Corzo L, Rodríguez S, Alcaraz M, Nebril L, Casas A, Fraile C, Cacabelos P, López L, Lanz A, Tellado I, Teijido O, Carril JC. Enfermedad de Parkinson: Nuevas soluciones a viejos problemas. EuroEspes J (Gen-T) 2017; 11:74-96.
Fernández-Novoa L, Corzo L, Seoane S, Cacabelos R. A Genomic approach to histamine function. J Genomic Med Pharmacogenomics 2017; 2(1):233-241.
Cacabelos R. Parkinson’s disease: From pathogenesis to pharmacogenomics. Int. J. Mol.Sci., 2017; 2017; 18:551. Doi:10.3390/ijms18030551.
Lombardi VRM, Carrera I, CacabelosR. In Vitro Screening for Cytotoxic Activity of Herbal Extracts, Evidence-Based Complementary and Alternative Medicine 2017, Article ID 2675631, 8 pages, 2017. doi:10.1155/2017/2675631.
Corzo L, Rodríguez S, Alejo R, Fernández-Novoa L, Aliev G, Cacabelos R. E-MHK-0103 (Mineraxin™): A Novel Nutraceutical with Biological Properties in Menopausal Conditions. Curr Drug Metab 2017; 18(1): 39-49.
Carrera I, Fernández-Novoa L, Sampedro C, Cacabelos R. Neuroprotective effect of atremorine in an experimental model of Parkinson’s Disease. Current Pharmaceutical Design 2017; 23:1-12.
Romero A, Parada E, González-Lafuente, Farré-Alins, Ramos E, Cacabelos R, Egea J. Neuroprotective effects of E-PodoFavalin-15999 (Atremroine®). CNS Neurosci Ther 2017; DOI: 10.111/cns.12693.
Arun M, Balamuralikrishnan B, Meenakshi RN, Kumar AK, Sureshkumar A, Kumar RKM, Haripriya KB, Muguresh E, Shanmughavel P, Suganthi R, Sasikala K, Cacabelos R. Cytogentic studies, MTHFR-C677T screening, and homocysteine levels in epileptic patients from South India. Trans Genetics Genomics 2017; 1:27-35.
Cacabelos, R., Carril, J.C., Cacabelos, P., Fernández-Novoa, L., Meyyazhagan, A. Pharmacogenetics of neurodegenerative Disorders. Internal Medicine Rev., 2017; 3(5):1-40.
Torrellas C, Carril JC, Cacabelos R. Optimization of antidepressant use with pharmacogenetic strategies. Cur Genomics 2017; 18:442-449.
Carril JC, Cacabelos R. Genetic risk factors in cerebrovascular disorders and cognitive deterioration. Cur Genomics 2017; 18:416-429.
Teijido O, Carril JC, Cacabelos R. Population-based study of risk polymorphisms associated with vascular disorders and dementia. Cur Genomics 2017; 18:430-441.
Lombardi VRM, Carrera I, Cacabelos R. Cardiovascular Disease associated risk factors: A possible link between nutrition and environmental contaminants. Nutrition and Food Toxicology 2017; 1(2): 70-81.
Cacabelos R. The incorporation of pharmacogenomics to drug development in neuropsychiatric disorders. Nov Appro Drug Des Dev 2017; 1(4): NAPDD.MS.ID.555569.
Cacabelos R. Personalized nutrition: Changing mentality and eating habits. Nutrition and Food Toxicology 2017; 1(3):96-97.
Cacabelos R, Meyyazhagan A, Carril JC, Teijido O. Epigenomics and proteomics of brain disorders. J Genomic Med Pharmacogenomics 2017; 2(1): 267-324.
Cacabelos R. Neuroepigenetics: Prospects and illusions. J Clin Epigenetics 2017; 3(3):35. DOI: 10.21676/2472-1158.100069.
Lombardi VRM, Carrera I, Cacabelos R. In vitro and in vivo cytotoxic effects of antigan against tumor cells. Experimental and Therapeutic Medicine 2017; DOI: 10.3892/etm.2017.5681.
Meyyazhagan A, Raman NM, Easwaran M, Balasubramanian B, Alagamuthu K, Kuchi Botha H, Shanmugam S, Inbaraj K, Ramesh Kumar M, Kumar P, Thangamani L, Piramanayagam S, Anand V, Mohd Y, Park S, Teijido O, Carril JC, Cacabelos R, Keshavaraoand S, Cacabelos R. Biochemistry, cytogenetics and DMD gene mutations in South Indian patients with Duchenne muscular dystrophy. Int J Hum Genet 2017; 17(3):126-134.
Cacabelos R. Some news on old concepts and the epigenetics of Alzheimer’s disease. J Clin Epigenetics 3(4):45. DOI: 10.21767/2472-1158.100079.
Lombardi VRM, Carrera I, Corzo L, Cacabelos R. Role of bioactive lipofishins in prevention of inflammation and colon cancer. Seminars in Cancer Biology 2017; https://doi.org/10.1016/j.semcancer.2017.11.012.
Carrera I, Fernández-Novoa L, Teijido O, Sampedro C, Seoane S, Lakshmana M, Cacabelos R. Comparative characterization profile of transgenic mouse models of Alzheimer’s disease. J Genomic Med Pharmacogenomics 2017; 2(1):331-337.

Libros y Capítulos

Cacabelos R, Torrellas C. Pharmacoepigenomics. In: Medical Epigenetics. T. Tollefsbol (Ed). Elsevier. http://dx.doi.org/10.1016/B978-0-12-803239-8.00032-6.
Cacabelos R, Carril JC, Teijido O. Pharmacogenomics and Epigenomics of Age-Related Neurodegenerative Disorders: Strategies for Drug Development. In : Vaiserman AM (Ed). Anti-aging Drugs: From Basic Research to Clinical Practice. RSC Drug Discovery Series 2017; 57:75-141. DOI:10.1039/9781782626602-00075.
Cacabelos R, Teijido O. Epigenetic drug Discovery for Alzheimer’s disease. In: Moskalev A, Vaiserman A. (Eds). Epigenetics of Aging and Longevity. Elsevier/Academic Press, London, UK, 2018; 453-495.
Cacabelos R, Teijido O. 2018. Epigenetics of Brain Aging. Chapter 74. In: R. Conn and J. Ram, eds.)(Vol 2). Handbook of Models for Human Aging (2nd Edition). Elsevier, San Diego, USA.
Cacabelos R, Lombardi V, Fernández-Novoa L, Carrera I, Cacabelos P, Corzo L, Carril JC, Teijido O. Basic and Clinical Studies with marine LipoFishins and vegetal Favalins in neurodegeneration and age-related disorders. In: Studies in Natural Products Chemistry. Atta-ur-Rahman Ed. Vol 59. Elsevier; 2018; https://doi.org/10.1016/B978-0-444-64179-3.00006-2.
Cacabelos R, Teijido O. Epigenetics of Brain Aging. In: Ram J and Conn PM, ed. Conn’s handbook of Models for Human Aging (2nd Edition). London (UK): Elsevier/Academic Press; 2018: p.1041-1066.
Informe de la Ponencia de Estudio sobre Genómica. Senado del Reino de España, 2019.
Cacabelos R (Ed.). Pharmacoepigenetics. Academic Press/Elsevier, Oxford, 2019.
Cacabelos R. Pharmacoepigenetcs: A long way ahead. In: Cacabelos R (Ed.) Pharmacoepigenetics. Academic Press/Elsevier, Oxford, 2019; xv-xvii.
Cacabelos R, Tellado I, Cacabelos P. The epigenetic machinery in the life cycle and pharmacoepigenetics. In: Cacabelos R (Ed.) Pharmacoepigenetics. Academic Press/Elsevier, Oxford, 2019; 1-100.
Cacabelos R. Pathoepigenetics: The role of epigenetic biomarkers in disease pathogenesis. In: Cacabelos R (Ed.) Pharmacoepigenetics. Academic Press/Elsevier, Oxford, 2019; 139-189.
Cacabelos R, Carril JC, Sanmartín A, Cacabelos P. Pharmacoepigenetic processors: Epigenetic drugs, Drug resistance, Toxicoepigenetics, and Nutriepigenetics. In: Cacabelos R (Ed.) Pharmacoepigenetics. Academic Press/Elsevier, Oxford, 2019; 191-424.
Cacabelos R. Epigenetics and pharmacoepigenetics of neurodevelopmental and neuropsychiatric disorders. In: Cacabelos R (Ed.) Pharmacoepigenetics. Academic Press/Elsevier, Oxford, 2019; 609-709.
Guerra J, Cacabelos R. Pharmacoepigenetics of vertigo and related vestibular disorders. In: Cacabelos R (Ed.) Pharmacoepigenetics. Academic Press/Elsevier, Oxford, 2019; 755-779.
Cacabelos R, Cacabelos P, Carril JC. Epigenetics and pharmacoepigenetics of age-related neurodegenerative disorders. In: Cacabelos R (Ed.) Pharmacoepigenetics. Academic Press/Elsevier, Oxford, 2019; 903-950.
Martínez-Iglesias O, Cacabelos R. Epigenetic treatment of neurodegenerative Disorders. In: Histone Modifications in Therapy. Castelo-Branco P, Jeronimo C (Ed). Academic Press/Elsevier. 2020; p. 311-335. https://doi.org/10.1016/B978-0-12-816422-8.00013-1.
Naidoo V, Martínez-Iglesias O, Cacabelos R. Targeting epigenetics as future treatments of trauma and stress-or-related disorders. Epidrugs and epinutraceuticals. En: Epigenetics of Stress and Stress Disorders.
Youssef NA (Ed). Chapter 20. Academic Press/Elsevier. https://doi.org/10.1016/B978-0-12-823039-8.00012-5 (2022).
Cacabelos R. Pharmacogenetics in Alzheimer’s disease drug discovery and personalized treatment. En: Alzheimer’s Disease Drug Development. Research and Development Ecosystem. Cummings J, Kinney J, Fillit H (Ed). Cambridge University Press, UK, pp. 404-417 (2022).
Cacabelos R, Naidoo V, Martínez-Iglesias O, Corzo L, Cacabelos N, Pego R, Carril JC. Pharmacogenomics of Alzheimer’s disease: Novel Strategies for Drug Utilization and Development. In: Pharmacogenomics in Drug Discovery and Development. Qing Y (Ed). Methods in Molecular Biology, Vol. 2547, pp. 275-287 (2022).